explore -WSS

explore

author：knowledge 2025-10-01 03:10:44 - browse：3

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： ASCO: AstraZeneca says CAR

WSS

Cord blood banking comes at a high cost to babies

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Connecting traumatic brain injury and domestic violence

Brain 'hot spot' may explain why African Americans feel greater pain

Did the public have the right to know Arthur Ashe had AIDS?

explore

explore

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

BMI, flaws aside, is found to be useful estimate of body fat in youth

Continuity nursing helped my family in our darkest PICU moments

Grail is spending more than ever lobbying Congress

Moonlake's readout produced a cash windfall. Risks remain

With trial win, GSK could get blood cancer drug back on market

Supreme Court strikes down use of affirmative action

PhRMA sues HHS over Medicare drug price negotiation

Tori Bowie and the unacceptable rates of Black maternal death

Pfizer's Covid pill remains 89% effective in final analysis, company says

knowledge

4th of July breaks record for highest global temperature ever measured

HIV drugs protect against transmission, even in unprotected sex

See how much Covid

Australia's humpback populations rebound raising hopes of marine scientists

Australia's humpback populations rebound raising hopes of marine scientists

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

knowledge

focus

focus

leisure time